Journal of Isfahan Medical School

Journal of Isfahan Medical School

Association between Latent Tuberculosis Infection and Clinical Severity of COVID-19

Document Type : Original Article (s)

Authors
Morteza Pourahmad 1
Mahnaz Momenzadeh 2
Somayeh Haghighipour 3
Nima Arezoomandi 4
Mahshid Maleki 5
Manijeh Shams 6
Firozeh Abbasi 6
Maryam Nasirian 7
1 Professor, Department of Infectious Diseases and Tropical Medicine, School of Medicine, Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Assistant Professor, Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
3 Assistant Professor, Department of Infectious Diseases and Tropical Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
6 Health unit, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
7 Professor, Department of Epidemiology and Biostatistics, School of Health, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v43.i840.1586
Abstract
Background: Considering the hypothesis of cross-immunity between Mycobacterium tuberculosis and SARS-CoV-2, this study aimed to determine the association between a positive tuberculosis skin test (PPD) as a marker for latent tuberculosis infection (LTBI) and COVID-19 disease severity.
Methods: This cross-sectional analytical study was conducted on 90 patients with confirmed COVID-19 who had been referred to Al-Zahra Hospital in Isfahan. Patients were divided into three groups: mild, moderate, and severe disease (30 patients in each group) according to standard guidelines. A tuberculin skin test (PPD) was performed for all participants, and a positive result was defined as an induration size ≥10 mm. Data were analyzed using SPSS version 24 and the chi-square test.
Findings: Among the 90 patients studied, 19 (21.1%) had a positive PPD test. Data analysis showed a statistically significant association between a positive PPD test result and the severity of COVID-19 disease (p < 0.001). 94.7% (18 out of 19) of patients with positive PPD were in the mild disease group. In contrast, none of the patients with severe COVID-19 (out of 30) had a positive PPD test. Furthermore, the presence of a BCG vaccine scar was not statistically significantly associated with the severity of COVID-19 disease (P = 0.9).
Conclusion: The results of the study suggest that latent tuberculosis infection (based on a positive PPD skin test) may be associated with the occurrence of milder forms of COVID-19. This may indicate a potential protective role of cellular immunity induced by Mycobacterium tuberculosis against the severity of SARS-CoV-2 infection.

Highlights

Morteza Pourahmad: Google Scholar

Mahnaz Momenzadeh: Google Scholar 

Somayeh Haghighipour: Google Scholar

Nima Arezoomandi: Google Scholar

Maryam Nasirian: Google Scholar

Keywords
COVID-19
Tuberculosis
Tuberculin Test
BCG Vaccine
Latent Tuberculosis

Subjects

1.     Ersin F, Kartal M. The determination of the perceived stress levels and health‐protective behaviors of nursing students during the COVID‐19 pandemic. Perspect Psychiatr Care 2021; 57(2):929-35.
2.     Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34(2): 327-31.
3.     Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020; 395(10236): 1545-6.
4.     Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 2020; 117(30): 17720-6.
5.     Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020 Mar 28: 2020-03.
6.     Salman S, Salem ML. The mystery behind childhood sparing by COVID-19. International Journal of Cancer and Biomedical Research 2020; 5: 11-3.
7.     Steinglass R. Routine immunization: an essential but wobbly platform. Glob Health Sci Pract 2013; 1(3): 295-301.
8.     Havers FP, Whitaker M, Self JL, Chai SJ, Kirley PD, Alden NB, et al. Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19 COVID-NET, 14 states, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(23): 851-7.
9.     Salman S, Salem ML. Routine childhood immunization may protect against COVID-19. Med Hypotheses 2020; 140: 109689.
10.  Shi DS. Hospitalizations of children aged 5–11 years with laboratory-confirmed COVID-19 COVID-NET, 14 states, March 2020–February 2020. MMWR Morbidity and Mortality Weekly Report. 2022; 71(16): 574-81.
11.  Sidiq KR, Sabir DK, Ali SM, Kodzius R. Does Early Childhood Vaccination Protect Against COVID-19? Front Mol Biosci 2020; 7: 120.
12.  Baskar P, Collins G, Dorsey-Cooper B, Pyle R, Nagel J, Dwyer D, et al. Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA. Clin Exp Immunol 1998; 111(2): 251-6.
13.  Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96(1 Pt 1): 29-35.
14.  Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis 2015; 212(12): 1930-8.
15.  e Silva RdF, Pitzurra R. What are the factors influencing the COVID-19 outbreak in Latin America? Travel Med Infect Dis 2020; 35: 101667.
16.  Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Guérin: what is the link? European urology oncology. 2020.
17.  Sharquie IK. BCG is a good immunotherapeutic agent for viral and autoimmune diseases: is it a new weapon against coronavirus (COVID-19)?. Electronic journal of general medicine. 2020; 17(6): 1-6.
18.  Berg RE, Cordes CJ, Forman J. Contribution of CD8+ T cells to innate immunity: IFN‐γ secretion induced by IL‐12 and IL‐18. European journal of immunology. 2002;32(10):2807-16.
19.  Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang S-Y, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 2018; 23(1): 89-100. e5.
20.  Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016; 13(10): e1002152.
21.  Dye C. Making wider use of the world's most widely used vaccine: Bacille Calmette–Guérin revaccination reconsidered. J R Soc Interface 2013; 10(87): 20130365.
22.  Haghighipour S, Salesi M, Keikhaei F, Tarrahi MJ, Khani Z, Salehi H. Changes in the Level of Antiphospholipid Antibodies (Anticardiolipin and Anti-β2-Glycoprotein-I) and Thromboembolic Indices in COVID-19 Patients during 3 Weeks. Int J Prev Med 2023; 14: 38.
23.  Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). n: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
24.  Pahal P, Pollard EJ, Sharma S. PPD Skin Test. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2025.
25.  Arslan Gulen T, Bayraktar M, Yaksi N, Kayabas U. Is the course of COVID‐19 associated with tuberculin skin test diameter? A retrospective study. J Med Virol 2022; 94(3): 1020-6.
26.  Madan M, Baldwa B, Raja A, Tyagi R, Dwivedi T, Mohan A, et al. Impact of latent tuberculosis on severity and outcomes in admitted COVID-19 patients. Cureus 2021; 13(11): e19882.
27.  Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu C, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020: 2020.03. 10.20033795.
28.  Moorlag SJCFM, Arts RJW, van Crevel R, Netea M. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019; 25(12): 1473-8.
29.  Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA 2020; 323(22): 2340-1.
30.  Sharma A, Kumar Sharma S, Shi Y, Bucci E, Carafoli E, Melino G, et al. BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? Cell Death Dis 2020; 11(7): 516.
31.  Sala G, Chakraborti R, Ota A, Miyakawa T. Association of BCG vaccination policy and tuberculosis burden with incidence and mortality of COVID-19. Medrxiv. 2020 Apr 6: 2020-03.
32.  Torun S, Ozkaya S, Şen N, Kanat F, Karaman I, Yosunkaya S, et al. The Relationship between COVID-19 Severity and Bacillus Calmette-Guerin (BCG)/Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study. Pathog Glob Health 2021; 115(6): 405-11. 
Journal of Isfahan Medical School
Volume 43, Issue 840
4th Week , January
January and February 2026
Pages 1586-1592

  • Receive Date 25 October 2025
  • Accept Date 26 October 2025